Eyal Agmoni
Founder @ Japan-Israel Hi-Tech Ventures
Eyal Agmoni is a Series A investor at Japan-Israel Hi-Tech Ventures focused on Medical Device and Pharmaceutical. Eyal Agmoni is the Founder of Japan-Israel Hi-Tech Ventures. Eyal Agmoni attended NYU Stern School of Business.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 90%
Last updated:
For AI agents: llms.txt
Industries Eyal Agmoni invests in
Stages Eyal Agmoni invests in
Countries Eyal Agmoni invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 3 (30%)
- Pharmaceutical 2 (20%)
- Artificial Intelligence 2 (20%)
- Apps 1 (10%)
- Drones 1 (10%)
Stage
- Series A 2 (20%)
- Venture - Series Unknown 2 (20%)
- Seed 1 (10%)
- Series B 1 (10%)
- Private Equity 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
XTEND
|
XTEND develops AI-assisted tactical Unmanned Aircraft Systems (UAS) and the XOS operating system for remote operations. Its platforms are designed for military, security, and industrial applications, enabling intuitive control and rapid deployment. XTEND's technology supports multi-platform control, exchangeable payloads, and integration withthird-party software for diverse mission needs. | $30M / Series B / Jul 15, 2025 | |
|
XTEND
|
XTEND develops AI-assisted tactical Unmanned Aircraft Systems (UAS) and the XOS operating system for remote operations. Its platforms are designed for military, security, and industrial applications, enabling intuitive control and rapid deployment. XTEND's technology supports multi-platform control, exchangeable payloads, and integration withthird-party software for diverse mission needs. | $40M / Series B / May 08, 2024 | |
Trobix Bio
|
Trobix Bio is a company that develops and commercializes antibacterial products. It has developed platform technologies called ActiSense and GOTrap for developing high-quality products that remove the threat of antimicrobial resistance. | $3M / Series A / Mar 30, 2023 | |
Zsquare
|
Zsquare has developed the only scalable endoscopic platform capable of transmitting high resolution images in flexible, single-use endoscopes, through polymeric fibers of any shape or size. Zsquare’s imaging technology outperforms existing technologies by delivering higher quality visualizations through smaller diameters than those found inreusable endoscopy systems.Zsquare’s polymeric fiber enables the housing of inexpensive optics with no electronics in a single-use shell, and expensive components in a detachable, reusable imaging core. This platform feature allows the use of a single core with various interchangeable shells which offer differing capabilities for different indications, facilitating any type of endoscopy procedure at a lower costs per-use. | $15M / Private Equity / Mar 01, 2022 | |
X-trodes
|
X-trodes is a technology start-up that develops unique wearable, wireless technology, and advanced analytics of biopotential signals. | $4.5M / Seed / Oct 18, 2021 | |
Pepticom Ltd.
|
Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $2.6M / Venture - Series Unknown / Mar 09, 2021 | |
|
Trobix Bio
|
Trobix Bio is a company that develops and commercializes antibacterial products. It has developed platform technologies called ActiSense and GOTrap for developing high-quality products that remove the threat of antimicrobial resistance. | $3M / Series A / Jul 29, 2020 | |
|
Pepticom Ltd.
|
Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $5M / Series A / Oct 24, 2019 | |
|
Zsquare
|
Zsquare has developed the only scalable endoscopic platform capable of transmitting high resolution images in flexible, single-use endoscopes, through polymeric fibers of any shape or size. Zsquare’s imaging technology outperforms existing technologies by delivering higher quality visualizations through smaller diameters than those found inreusable endoscopy systems.Zsquare’s polymeric fiber enables the housing of inexpensive optics with no electronics in a single-use shell, and expensive components in a detachable, reusable imaging core. This platform feature allows the use of a single core with various interchangeable shells which offer differing capabilities for different indications, facilitating any type of endoscopy procedure at a lower costs per-use. | $10M / Venture - Series Unknown / Feb 27, 2019 | |
|
Pepticom Ltd.
|
Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $6.6M / Series A |
Co-Investors
Japan-Israel Hi-Tech Ventures is a venture fund operated by Singapore-based asset management firm Chartered Group.
Japan-Israel Hi-Tech Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Eyal Agmoni
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eyal Agmoni invest in?
Eyal Agmoni invests primarily in Medical Device, Pharmaceutical and Artificial Intelligence startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eyal Agmoni?
Public channels for Eyal Agmoni include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eyal Agmoni last invest?
The most recent investment recorded for Eyal Agmoni closed in Jul 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
